Skip to content

Study · Observational study · n = 15 · 2023

2 results

Parents' Experience of Administering Vosoritide: A Daily Injectable for Children with Achondroplasia.

NiMhurchadha S, Butler K, Argent R, Palm K, Baujat G, Cormier-Daire V, Mohnike K

Advances in therapy5 Apr 2023Cited by 9 (Europe PMC)

PMID37017912 (opens in a new tab)PMCIDPMC10129947 (opens in a new tab)DOI10.1007/s12325-023-02496-z (opens in a new tab)PepBankPUB-37017912
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanObservational studyOther

    Parents chose vosoritide hoping to reduce future complications and increase height for independence, while considering severe side effects.

    In plain wordsParents chose vosoritide hoping to reduce future complications and increase height for independence, while considering severe side effects.

    Peptide
    Vosoritide
    Outcome
    Not applicableTreatment decision factors
    Study

    n = 15

    Outcome group
    Treatment Experience · Whole body
    Studied dose
    Dose not stated · injection · 6 weeks to 13 monthsAs given in this study (human).

    Source sentences

    Summary
    (2) treatment understanding and decision-making, which found that their decision to take treatment is based on a desire to relieve future medical complications and increase height for improved independence, and they consider the extent to which the treatment has severe side effects;
    3 context sentences
    Summary · context
    Qualitative telephone interviews were conducted with parents of children being treated with vosoritide in France and Germany.
    Summary · context
    Fifteen parents participated in telephone interviews in September and October 2022.
    Summary · context
    The median age of children in this sample was 8 years old (range 3-13 years) and children had been taking treatment from 6 weeks to 13 months.
  2. 02HumanObservational studyOther

    Parents reported that hospital initiation and training for vosoritide varied considerably within and between France and Germany.

    In plain wordsParents reported that hospital initiation and training for vosoritide varied considerably within and between France and Germany.

    Peptide
    Vosoritide
    Outcome
    Not applicableTreatment initiation and training
    Study

    n = 15

    Outcome group
    Treatment Experience · Whole body
    Studied dose
    Dose not stated · injection · 6 weeks to 13 monthsAs given in this study (human).

    Source sentences

    Summary
    (3) training and initiation, which showed that the hospital initiation and training sessions varied considerably both across and within countries, with different treatment centres taking different approaches;
    3 context sentences
    Summary · context
    Qualitative telephone interviews were conducted with parents of children being treated with vosoritide in France and Germany.
    Summary · context
    Fifteen parents participated in telephone interviews in September and October 2022.
    Summary · context
    The median age of children in this sample was 8 years old (range 3-13 years) and children had been taking treatment from 6 weeks to 13 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.